Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.
Marek L KowalskiIoana AgacheSevim BavbekArzu BakirtasMiguel BlancaGrażyna BochenekMatteo BoniniEnrico HefflerLudger KlimekTanya M LaidlawJoaquim MullolEwa Niżankowska-MogilnickaHae-Sim ParkMarek SanakMario Sanchez-BorgesSilvia Sanchez-GarciaGlenis ScaddingMasami TaniguchiTorres María JoséAndrew A WhiteAleksandra WardzyńskaPublished in: Allergy (2018)
NSAID-exacerbated respiratory disease (N-ERD) is a chronic eosinophilic, inflammatory disorder of the respiratory tract occurring in patients with asthma and/or chronic rhinosinusitis with nasal polyps (CRSwNP), symptoms of which are exacerbated by NSAIDs, including aspirin. Despite some progress in understanding of the pathophysiology of the syndrome, which affects 1/10 of patients with asthma and rhinosinusitis, it remains a diagnostic and therapeutic challenge. In order to provide evidence-based recommendations for the diagnosis and management of N-ERD, a panel of international experts was called by the EAACI Asthma Section. The document summarizes current knowledge on the pathophysiology and clinical presentation of N-ERD pointing at significant heterogeneity of this syndrome. Critically evaluating the usefulness of diagnostic tools available, the paper offers practical algorithm for the diagnosis of N-ERD. Recommendations for the most effective management of a patient with N-ERD stressing the potential high morbidity and severity of the underlying asthma and rhinosinusitis are discussed and proposed. Newly described sub-phenotypes and emerging sub-endotypes of N-ERD are potentially relevant for new and more specific (eg, biological) treatment modalities. Finally, the document defines major gaps in our knowledge on N-ERD and unmet needs, which should be addressed in the future.
Keyphrases
- chronic rhinosinusitis
- chronic obstructive pulmonary disease
- lung function
- allergic rhinitis
- respiratory tract
- healthcare
- case report
- clinical practice
- oxidative stress
- cystic fibrosis
- risk assessment
- cardiovascular events
- cardiovascular disease
- acute coronary syndrome
- current status
- percutaneous coronary intervention
- antiplatelet therapy
- anti inflammatory drugs